Abstract
Granulocyte colony-stimulating factor is a potent stimulator for neutrophils in the circulation as well as those progenitors to be increased and be grown in the bone marrow. Recombinant forms of this colony-stimulating factor, therefore, are widely using in the various kinds of clinical fields such as for the treatment of bone marrow suppression after cancer chemotherapy and for the treatment of myelodysplastic disorders. One of the physiological function of granulocyte colony-stimulating factor is to activate neutrophils enough to fight against invaded microbes and others, thus it is hoped to be used for the treatment of various kinds of infectious diseases even while the host has a normal number of circulating neutrophils and normal bone marrow. The future possible clinical usage of granulocyte colony-stimulating factor as for the immunomodulation against various kinds of insults to the human is reviewed.
Keywords: granulocyte colony-stimulating factor, sepsis, bone marrow suppression, myelodysplastic disorders
Current Pharmaceutical Design
Title: Granulocyte Colony-stimulating Factor as the Expecting Sword for the Treatment of Severe Sepsis
Volume: 9 Issue: 14
Author(s): Atsuo Murata
Affiliation:
Keywords: granulocyte colony-stimulating factor, sepsis, bone marrow suppression, myelodysplastic disorders
Abstract: Granulocyte colony-stimulating factor is a potent stimulator for neutrophils in the circulation as well as those progenitors to be increased and be grown in the bone marrow. Recombinant forms of this colony-stimulating factor, therefore, are widely using in the various kinds of clinical fields such as for the treatment of bone marrow suppression after cancer chemotherapy and for the treatment of myelodysplastic disorders. One of the physiological function of granulocyte colony-stimulating factor is to activate neutrophils enough to fight against invaded microbes and others, thus it is hoped to be used for the treatment of various kinds of infectious diseases even while the host has a normal number of circulating neutrophils and normal bone marrow. The future possible clinical usage of granulocyte colony-stimulating factor as for the immunomodulation against various kinds of insults to the human is reviewed.
Export Options
About this article
Cite this article as:
Murata Atsuo, Granulocyte Colony-stimulating Factor as the Expecting Sword for the Treatment of Severe Sepsis, Current Pharmaceutical Design 2003; 9 (14) . https://dx.doi.org/10.2174/1381612033454982
DOI https://dx.doi.org/10.2174/1381612033454982 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Therapeutic AIDS Vaccines
Current Pharmaceutical Design Bacteriocins Active Against Multi-Resistant Gram Negative Bacteria Implicated in Nosocomial Infections
Infectious Disorders - Drug Targets Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Determination of Three Tyrosine Kinase Inhibitors and One Active Metabolite by an Identical and Validated Ultra-performance Liquid Chromatography-DAD Method in Human Plasma
Current Pharmaceutical Analysis Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Monitoring of Treatment-Induced Apoptosis in Oncology with PET and SPECT
Current Pharmaceutical Design Neurodevelopment in Schizophrenia: The Role of the Wnt Pathways
Current Neuropharmacology Editorial (Thematic Issue: Unlocking the Potential of Stem Cells in Cell Therapy, Drug Delivery and Drug Discovery)
Current Drug Delivery Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Excessive Oxidative Stress in the Synergistic Effects of Shikonin on the Hyperthermia-Induced Apoptosis
Current Molecular Medicine Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Cardiovascular & Hematological Disorders-Drug Targets Molecular Docking and 3D-QSAR Studies on Quinolone-based HDAC Inhibitors
Letters in Drug Design & Discovery Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Development and Validation of a Rapid and Sensitive Assay for Simultaneous Quantification of Lenalidomide and Dexamethasone in Human Plasma by Liquid Chromatography Coupled to Tandem Mass-Spectrometry
Current Pharmaceutical Analysis Rho-Signaling Pathways in Chronic Myelogenous Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Machine Learning for Childhood Acute Lymphoblastic Leukaemia Gene Expression Data Analysis: A Review
Current Bioinformatics Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews